11-Methoxyuncarine CCAS# 61665-08-5 |
- Vineridine
Catalog No.:BCN5286
CAS No.:3489-06-3
- Caboxine A
Catalog No.:BCN5715
CAS No.:53851-13-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 61665-08-5 | SDF | Download SDF |
PubChem ID | 91884806 | Appearance | Powder |
Formula | C22H26N2O5 | M.Wt | 398.5 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | methyl (1S,4aS,5aS,6R,10aS)-6'-methoxy-1-methyl-2'-oxospiro[1,4a,5,5a,7,8,10,10a-octahydropyrano[3,4-f]indolizine-6,3'-1H-indole]-4-carboxylate | ||
SMILES | CC1C2CN3CCC4(C3CC2C(=CO1)C(=O)OC)C5=C(C=C(C=C5)OC)NC4=O | ||
Standard InChIKey | SRKHGHLMEDVZRX-XZLQSYOBSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
11-Methoxyuncarine C Dilution Calculator
11-Methoxyuncarine C Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5094 mL | 12.5471 mL | 25.0941 mL | 50.1882 mL | 62.7353 mL |
5 mM | 0.5019 mL | 2.5094 mL | 5.0188 mL | 10.0376 mL | 12.5471 mL |
10 mM | 0.2509 mL | 1.2547 mL | 2.5094 mL | 5.0188 mL | 6.2735 mL |
50 mM | 0.0502 mL | 0.2509 mL | 0.5019 mL | 1.0038 mL | 1.2547 mL |
100 mM | 0.0251 mL | 0.1255 mL | 0.2509 mL | 0.5019 mL | 0.6274 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Furomollugin
Catalog No.:BCN4141
CAS No.:61658-41-1
- MK 212 hydrochloride
Catalog No.:BCC6856
CAS No.:61655-58-1
- Propargyl p-toluenesulfonate
Catalog No.:BCN2266
CAS No.:6165-76-0
- Propargyl benzenesulfonate
Catalog No.:BCN2247
CAS No.:6165-75-9
- Protopine hydrochloride
Catalog No.:BCN5345
CAS No.:6164-47-2
- Amfenac Sodium Monohydrate
Catalog No.:BCC4620
CAS No.:61618-27-7
- Songoroside A
Catalog No.:BCN3988
CAS No.:61617-29-6
- (-)-Sparteine Sulfate Pentahydrate
Catalog No.:BCC8273
CAS No.:6160-12-9
- Acetylcysteine
Catalog No.:BCC3716
CAS No.:616-91-1
- H-DL-Nle-OH
Catalog No.:BCC3301
CAS No.:616-06-8
- 13-Hydroxy-8,11,13-podocarpatrien-18-oic acid
Catalog No.:BCN1399
CAS No.:61597-83-9
- 15,16-Epoxy-12R-hydroxylabda-8(17),13(16),14-triene
Catalog No.:BCN1400
CAS No.:61597-55-5
- Neridienone B
Catalog No.:BCN4143
CAS No.:61671-56-5
- Trimethyl[3-(methylthio)propyl]ammonium(1+)
Catalog No.:BCN1398
CAS No.:61672-50-2
- 3-(Dimethylsulfonio)-N,N,N-trimethylpropanaminium(2+)
Catalog No.:BCN1397
CAS No.:61672-51-3
- H-Alaninol
Catalog No.:BCC2731
CAS No.:6168-72-5
- OMDM-2
Catalog No.:BCC5814
CAS No.:616884-63-0
- Ethyl vanillate
Catalog No.:BCN3670
CAS No.:617-05-0
- 2-Hydroxy-1-methoxyanthraquinone
Catalog No.:BCN3091
CAS No.:6170-06-5
- 2-Chloro-1,4-phenylenediamine sulfate
Catalog No.:BCN8435
CAS No.:61702-44-1
- W-5 hydrochloride
Catalog No.:BCC6621
CAS No.:61714-25-8
- W-7 hydrochloride
Catalog No.:BCC6622
CAS No.:61714-27-0
- Fluvoxamine maleate
Catalog No.:BCC1215
CAS No.:61718-82-9
- Methyl 2-(5-acetyl-2,3-dihydrobenzofuran-2-yl)propenoate
Catalog No.:BCN1396
CAS No.:617722-55-1
Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection.[Pubmed:29024739]
Pharmacol Ther. 2018 Mar;183:118-126.
Hepatitis C virus (HCV) is a global health problem, because infection frequently leads to chronic hepatitis C eventually progressing to liver cirrhosis and liver cancer. Improved insights into the HCV replication cycle and the role of HCV non-structural proteins have recently enabled to identify drugs directly acting on specific HCV target structures. Agents from three drug classes have been developed and approved by the health authorities. Combinations of two or more drugs from different classes achieve high (>90%) HCV clearance rates and are well tolerated. This interferon-free DAA (direct antiviral agent) therapy has revolutionized antiviral therapy in hepatitis C so that successful hepatitis C treatment can be offered to virtually all patients irrespective of their co-morbidity. This review provides an overview over currently approved regimens and outlines their use in clinical practice. In addition potential short-comings of the current therapeutic options such as drug-drug interactions and selection of viral resistance are addressed. DAA combination therapy has the potential to obtain global control over hepatitis C. However, easy access to DAAs, availability of reliable HCV diagnostics, and affordable costs remain still important goals, which must be reached to globally eliminate hepatitis C.
Discovery of HLA-C*14:87, a novel HLA-C*14 variant, in a Taiwanese individual.[Pubmed:29024503]
HLA. 2018 Jan;91(1):72-73.
One nucleotide substitution at residue 526 of the HLA-C*14:15 results in a novel allele, HLA-C*14:87.
Comparative analysis of clinics, pathologies and immune responses in BALB/c and C57BL/6 mice infected with Streptobacillus moniliformis.[Pubmed:29024796]
Microbes Infect. 2018 Feb;20(2):101-110.
Streptobacillus (S.) moniliformis is a rat-associated zoonotic pathogen that occasionally causes disease in other species. We investigated the working hypothesis that intranasal infection might lead to different immune responses in C57BL/6 and BALB/c mice associated with distinct pathologies. This study confirmed with 75% mortality the known high susceptibility of C57BL/6 mice to Streptobacillus moniliformis infection in comparison to BALB/c mice which did not develop signs of disease. Main pathologies in C57BL/6 mice were purulent to necrotizing lymphadenitis and pneumonia. Significant seroconversion was recorded in surviving mice of both strains. Differentiation of IgG-subclasses revealed mean ratios of IgG2b to IgG1 below 0.5 in sera of all mice prior to infection and of BALB/c mice post infection. In contrast, C57BL/6 mice had a mean IgG2b/IgG1 ratio of 2.5 post infection indicating a Th1 immune response in C57BL/6 versus a Th2 response in BALB/c mice. Evaluation of different sentinel systems revealed that cultural and serological investigations of these animals might not be sufficient to detect infection. In summary, an intranasal S. moniliformis infection model in C57BL/6 mice leading to purulent to necrotizing inflammations in the lung, the lymph nodes and other organs associated with a Th1 immune response is described.
Pubertally Initiated High-Fat Diet Promotes Mammary Tumorigenesis in Obesity-Prone FVB Mice Similarly to Obesity-Resistant BALB/c Mice.[Pubmed:29024822]
Transl Oncol. 2017 Dec;10(6):928-935.
Premenopausal breast cancer is associated with increased animal fat consumption among normal-weight but not overweight women. Our previous findings in obesity-resistant BALB/c mice showed that a diet high in saturated animal fat (HFD) promotes mammary tumorigenesis in both DMBA carcinogenesis and Trp53-null transplant models. Having made these observations in BALB/c mice, which have very modest HFD weight gain, we determined the effects of HFD in FVB mice, which gain significant weight on HFD. Three-week-old FVB mice fed a low-fat diet or HFD were subjected to 7,12-dimethylbenz[a]anthracene-induced carcinogenesis. Like BALB/c mice, HFD promoted mammary tumorigenesis. Development of tumors largely occurred prior to mice becoming obese, indicating the role of animal-derived HFD rather than resulting obesity in tumor promotion. Also similar to BALB/c mice, early-occurring adenosquamous mammary tumors were abundant among HFD-fed FVB mice. Tumors from HFD mice also had increased intra-tumor M2 macrophages. Prior to tumor development, HFD accelerated normal mammary gland development and increased mammary M2 macrophages, similarly to BALB/c mice. The promotional effects of puberty-initiated HFD on carcinogen-induced mammary cancer are thus largely weight gain-independent. Like BALB/c mice, HFD promoted adenosquamous tumors, suggesting a role for early age HFD in promoting this subtype of triple negative mammary cancer. M2 macrophage recruitment was common to both mouse strains. We speculate that a similar effect of HFD on immune function may contribute to epidemiological findings of increased breast cancer risk in young, premenopausal, normal-weight women who consume a diet high in saturated animal fat.